Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
2009-014644-11Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2009
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing Rasagiline 1 mg with Placebo (2 arms). Primary endpoint: Change in total UMSARS score from baseline to Week 48/Termination. Started Sep 2009; status: completed.
02
Drugs
rasagiline
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2009-014644-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014644-11.